(HealthDay News) — A model with 4 categories has been developed to stratify patients with symptomatic long bone metastases (LBM) based on their expected survival, according to an article published online in the Journal of Bone & Joint Surgery.
Julie J. Willeumier, MD, from the Leiden University Medical Centre in the Netherlands, and colleagues conducted a multicenter retrospective study of 1520 patients treated for symptomatic LBM between 2000 and 2013. Using an existing classification system, primary tumors were categorized into favorable, moderate, or unfavorable clinical profiles.
The researchers found that the median overall survival was 7.4 months. Twelve prognostic categories were created based on the independent prognostic factors: the clinical profile, Karnofsky Performance Score, and presence of visceral and/or brain metastases. The discriminatory ability, assessed with the Harrell C-statistic, was 0.70. To easily stratify patients, a flowchart was developed. The 12 categories were narrowed to 4 categories with clinical consequences using cutoff points for clinical decision making. For the 4 categories, median survival was 21.9, 10.5, 4.6, and 2.2 months, respectively.
“This study presents a model to easily stratify patients with symptomatic LBM according to their expected survival,” the authors write. “The simplicity and clarity of the model facilitate and encourage its use in the routine care of patients with LBM, to provide the most appropriate treatment for each individual patient.”
Willeumier JJ, van der Linden YM, van der Wal CWPG, et al. An Easy-to-Use Prognostic Model for Survival Estimation for Patients with Symptomatic Long Bone Metastases. J Bone Join Surg. doi: 10.2106/JBJS.16.01514